Evaluating HBVZ10-Based Therapied for cccDNA Clearance: Virological Foundation and Synergistic Combinations
Award Notice Posted
- Solicitation number
- PHS2025-1
- Agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Awarded
- to Hbvtech, L.l.c
- Set-aside
- Total Small Business
Opportunity facts
- Contract number
- 75N93025C00023 Federal contract award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Place of performance
- Germantown, Maryland 20874, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, has awarded contract 75N93025C00023 valued at $2,656,170.00 to HBVTECH, L.L.C. for research services titled "Evaluating HBVZ10-Based Therapies for cccDNA Clearance: Virological Foundation and Synergistic Combinations." This total small business set-aside contract focuses on developing therapeutic approaches for hepatitis B virus treatment, specifically targeting covalently closed circular DNA (cccDNA) clearance through HBVZ10-based therapies and examining potential synergistic drug combinations. The contract was awarded on August 1, 2025, representing significant federal investment in advancing antiviral research and therapeutic development for hepatitis B treatment.
Notice text
Awarded contract 75N93025C00023 to HBVTECH, L.L.C for 2656170.00 on 2025-08-01.
Notice history
6 of 10 notices listed here. See the rest on GovTribe.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity